
ã第2éšãæé£ã®ãè¡ç³å€ã¹ãã€ã¯ããååäžã®IQãç Žå£ããããšãŒã«å€§åŠçã®ç ç©¶ã§èŠãè³ç§åŠã
ãã¯ããããããŸããæé·ãªã¿ã¯ã§ãïŒ
â»ããããªã¹ãã·ãªãŒãºã®ãçªå€ç·š 第2éšãããå±ãããŸãïŒ
â»note31äœç®
ååïŒçªå€ç·š 第1éšïŒã§ã¯
ãæé£ã®ã¡ãã¥ãŒãéžã¶ããšèªäœã決å®ç²åŽãèµ·ãããè£å€å®ã®ããã«å€æåãäœäžãããŠããŸãããšããäºå®ããäŒãããŸãã
ããªãã»ã©ã
ãè¿·ãã®ãè¯ããªããªãã
ãæ¯ææè»œã«ããããšé£ã¹ãããã
ãèåãã³ãçã猶ã³ãŒããŒã
ãããŒã¹ãã«ãžã£ã ãå¡ã£ãŠæžãŸããã°ããã®ã§ã¯ïŒã

ããæã£ãæ¹âŠâŠã¡ãã£ãšåŸ ã£ãŠãã ããïŒïŒïŒ
ããã«
ç§ãã¡ã®ååäžã®éäžåã跡圢ããªãå¹ãé£ã°ã
ããäžã€ã®è¶
å¶æªãªãã©ãããæœãã§ããã®ã§ã
ããã
è¿å¹Žå»åŠãè³ç§åŠã®äžçã§éåžžã«æ³šç®ãããŠãã
ãè¡ç³å€ã¹ãã€ã¯ïŒGlycemic SpikeïŒã°ã©ã€ã·ãŒããã¯ã»ã¹ãã€ã¯ïŒãã§ã

ä»åã¯
æé£ã®éžã³æ¹ãããã«ããŠè³ã®ãšãã«ã®ãŒäŸçµŠãæ¢ã
ç§ãã¡ã®å€æåãå®è¡æ©èœã壿» ãããã®ã
ææ°ã®ç ç©¶ããŒã¿ãšãšãã«è§£ãæãããŠãããŸãïŒ
1. èåãã³ãšçŒ¶ã³ãŒããŒãæããè¡ç³å€ã®ãžã§ããã³ãŒã¹ã¿ãŒã
æã®å¿ããæéã«
æè»œã ãããšããçç±ã§ä»¥äžã®ãããªæé£ãéžãã§ããŸãããïŒ
ç ç³ãã£ã·ãã®èåãã³ããããã·ã¥
çã猶ã³ãŒããŒãã«ãã§ãªã¬
é£ãã³ïŒããŒã¬ãªã³ããžã£ã ïŒæç©ãžã¥ãŒã¹
ããã
ã粟補ãããçæ°Žåç©ãç ç³ïŒé«GIé£åïŒãã
ç©ºè ¹ç¶æ ã®èã«äžæ°ã«æŸã蟌ããš
è¡æ¶²äžã®ãããŠç³æ¿åºŠïŒè¡ç³å€ïŒãåçŽç«ã¡äžããã§æ¥æ¿ã«äžæããŸã
ããããè¡ç³å€ã¹ãã€ã¯ãã§ã
æ¥æ¿ã«äžãã£ãè¡ç³å€ãäžããããšããŠ
äœå ã§ã¯èµèãã
ãã€ã³ã¹ãªã³ããšãããã«ã¢ã³ã倧éã«åæ³ãããŸã
ããã
ãã®ã€ã³ã¹ãªã³ãéå°ã«åºãããããšã§
ä»åºŠã¯è¡ç³å€ãæ¥éäžïŒãªã¢ã¯ãã£ãäœè¡ç³ / åå¿æ§äœè¡ç³ïŒãèµ·ãããŠããŸãã®ã§ã
ã€ãŸã
æé£åŸã«ããªãã®äœå ã§ã¯
ãè¡ç³å€ã®ä¹±é«äžãžã§ããã³ãŒã¹ã¿ãŒããçºçããŠããããšã«ãªããŸã

2. ãšãŒã«å€§åŠçã®ç ç©¶ã瀺ããäœè¡ç³ãªããŠã³ãããšè³æ©èœã®ããŠã³
ãè¡ç³å€ãäžããããããããããããšãªãã§ããïŒã
ãšæããããããŸãã
ããã
è³ç§åŠçã«èŠããš
ããã¯èŽåœçãªäºæ ã§ã
ãªããªã
人éã®è³ïŒç¹ã«æèãæææ±ºå®ãåžãåé åéïŒã
çŽæ¥å©çšã§ããå¯äžã®äž»èŠãšãã«ã®ãŒæºã¯
ãè¡æ¶²äžã®ãããŠç³ïŒã°ã«ã³ãŒã¹ïŒïŒãã ããã§ã
â»è¡æ¶²äžã®ãããŠç³ïŒé£äºã§æåããçæ°Žåç©ãªã©ãåè§£ãããŠè¡æ¶²äžã«å
¥ã£ããã®ã§ãå
šèº«ã®çްèãè³ã®éèŠãªãšãã«ã®ãŒæºãšãªãæ é€çŽ ã®ããš
ãšãŒã«å€§åŠãããŒããŒã倧åŠãã¯ãããšããå€ãã®ç ç©¶æ©é¢ã§è¡ãããè³ç§åŠãšä»£è¬ã«é¢ããç ç©¶ã§ã¯ãè¡ç³å€ã®æ¥æ¿ãªå€åïŒè¡ç³å€ã¹ãã€ã¯ïŒããåé èã®ãããã¯ãŒã¯ãå·ã€ããèšç»æ§ãè«ççæèãåžããå®è¡æ©èœïŒExecutive FunctionïŒãã«æ·±å»ãªæªåœ±é¿ãäžããããšãå®èšŒãããŠããŸãã
ãšãŒã«å€§åŠã®ç ç©¶ïŒ Lower brain glucose levels found in people with obesity and type 2 diabetesïŒè¥æºã2åç³å°¿ç æ£è ã«ãããè³å ãããŠç³ã¬ãã«ã®äœäžãšè³æ©èœäœäžãªã¹ã¯ïŒ
ããŒããŒã倧åŠç³»åã®ç ç©¶ïŒ Multi-Scale Glycemic Variability: A Link to Gray Matter Atrophy and Cognitive Decline in Type 2 DiabetesïŒå€ã¹ã±ãŒã«è¡ç³å€åæ§ïŒ2åç³å°¿ç ã«ããã倧è³ç®è³ªïŒ»ç°çœè³ªïŒœã®èçž®ãšèªç¥æ©èœäœäžãšã®é¢é£ïŒ
äžåœã»åå·å€§åŠãªã©ã®ç ç©¶ããŒã ïŒ Executive Function and Diabetes: A Clinical Neuropsychology Perspective ïŒå®è¡æ©èœãšç³å°¿ç ïŒèšåºç¥çµå¿çåŠç芳ç¹ããïŒ
â ïž ããã§äžæŠãç¥èã®ãã«ã³ãããïŒã«ã³ãïŒãïŒ
ãå®è¡æ©èœïŒExecutive FunctionïŒãšã°ãŒã¯ãã£ãã»ãã¡ã³ã¯ã·ã§ã³ïŒã ç®æšãéæããããã«ãèªåã®æèãè¡åãå¶åŸ¡ã»ç®¡çããé«åºŠãªèªç¥èœåã®ããšãèšç»ç«æ¡ãã¯ãŒãã³ã°ã¡ã¢ãªãèªæãžã®èªå¶å¿ãè«ççãªæææ±ºå®ãªã©ãå«ãŸããã
æ¥æ¿ãªã€ã³ã¹ãªã³åæ³ã«ãã£ãŠ
è¡ç³å€ãäœè¡ç³ç¶æ ãŸã§èœã¡èŸŒããš
è³ãžã®ãããŠç³äŸçµŠãã¹ãããããŸã
ãã®çµæãè³å ã§äœãèµ·ããããšãããšâŠâŠ
æ¿ããç æ°ãšåŠæ æïŒ åå10æé ã«ççãªç æ°ã襲ãã(=_=)
ã¯ãŒãã³ã°ã¡ã¢ãªã®äœäžïŒ ç°¡åãªèšç®ãã¹ãèŠèœãšããå¢ããã( ïŸÐ`)
èªå¶å¿ïŒæå¿åïŒã®äœäžïŒ ã€ã©ã€ã©ãããããªããè¡åçãªå€æãããŠããŸã(ïŒïŸÐïŸ)
ã€ãŸã
æããæè»œãªçããã³ãªã©ãéžãã§ããŸããš
ãéžæã«ããæ±ºå®ç²åŽã
ãš
ãè¡ç³å€ã¹ãã€ã¯ã«ããè³ã®ãšãã«ã®ãŒåãã
ãšãã
ããã«ãã³ããé£ããããšã«ãªãã®ã§ãïŒ

3. é žåã¹ãã¬ã¹ãåé åéã®äŒéã¹ããŒããéããã
ããã«æãããã®ã¯
è¡ç³å€ã¹ãã€ã¯ãè³ã®ç¥çµçްèã«çŽæ¥äžããç©ççãªãã¡ãŒãžã§ã
çæéã§è¡ç³å€ãä¹±é«äžãããš
äœå ã§
ãæŽ»æ§é žçŽ ãã倧éã«çºçããŸã
ãããè³ã®åŸ®çްãªè¡ç®¡ãç¥çµçްèã«
ãé žåã¹ãã¬ã¹ïŒäžæçãªåŸ®å°ççïŒããåŒãèµ·ãããŸã
è¿å¹Žã®ä»£è¬ãšè³æ©èœã«é¢ããç ç©¶ïŒDavis et al. ãªã©ã®ã¬ãã¥ãŒïŒã«ãããšãè¡ç³å€ã®æ¥æ¿ãªå€åïŒè¡ç³å€ã¹ãã€ã¯ïŒã«ãã£ãŠè³å ã«åŒ·åãªé žåã¹ãã¬ã¹ãåŒãèµ·ããããããšãåãã£ãŠããŸãããã®ã¹ãã¬ã¹ã«ãããè³ã®æé«åžä»€å¡ã§ããåé åéïŒåé èïŒã®ç¥çµäŒéåè·¯ã®çµã³ã€ããäžæçã«åŒ±ãŸããè³ã®åŠçã¹ããŒããè«ççæèåïŒå®è¡æ©èœïŒãç©ççã«äœäžããããšã確èªãããŠããŸãã
ãONE PIECEãã§äŸãããªã
æé£ã«çããã³ãé£ã¹ãç¬éã«
海楌ç³ã®é åãã¯ããããäžã«ããŒã©ã³ã®æ¯ã济ã³ããããªç¶æ
 ããã§ã¯
ã©ããªã«æ°åãå ¥ããŠãã¹ã¯ã«åãã£ããšããã§
èŠæ°ïŒããã©ãŒãã³ã¹ïŒãåºããã¯ãããããŸããããïŒç¬ïŒ

ã€ãŸã
æã®ããã©ãŒãã³ã¹ãæå€§åããããã«å¿ èŠãªã®ã¯
æé£ããäœã«ãããè¿·ãæéãããŒãã«ããïŒæ±ºå®ç²åŽã®æé€ïŒ
è¡ç³å€ããæ¥äžæãããªããã¡ãã¥ãŒã«åºå®ããïŒè¡ç³å€ã¹ãã€ã¯ã®é²æ¢ïŒ
ãšããããã«ã®ããã¯ãªã®ã§ãïŒ

ã§ã¯
å¿ãããµã©ãªãŒãã³ã§ããç§ãã¡ã
ææ¥ããã¹ãã¬ã¹ãªãå®è·µã§ãã
ãç§åŠçã«æåŒ·ã®æé£åºå®åïŒå¶æåïŒãããã³ã«ããšã¯
å ·äœçã«ã©ã®ãããªãã®ãªã®ã§ããããïŒ
次åãçªå€ç·š 第3éšãã§ã¯
誰ã§ã15ç§ã§æºåã§ããŠ
ååäžã®IQããã¯äžããã
ãæé£ã®å¶æå3ã€ã®æ¡ä»¶ããšå ·äœã¡ãã¥ãŒãå ¬éããŸãïŒ
ã©ãããæ¥œãã¿ã«ïŒ
æåŸ ãã¡ ãŒãã¿ã€ïŒïŒ
ð¡ æ ¹æ ã»åèæç®
ãšãŒã«å€§åŠã®ç ç©¶ïŒ Lower brain glucose levels found in people with obesity and type 2 diabetesïŒè¥æºã2åç³å°¿ç
æ£è
ã«ãããè³å
ãããŠç³ã¬ãã«ã®äœäžãšè³æ©èœäœäžãªã¹ã¯ïŒ
ããŒããŒã倧åŠç³»åã®ç ç©¶ïŒ Multi-Scale Glycemic Variability: A Link to Gray Matter Atrophy and Cognitive Decline in Type 2 DiabetesïŒå€ã¹ã±ãŒã«è¡ç³å€åæ§ïŒ2åç³å°¿ç
ã«ããã倧è³ç®è³ªïŒ»ç°çœè³ªïŒœã®èçž®ãšèªç¥æ©èœäœäžãšã®é¢é£ïŒ
äžåœã»åå·å€§åŠãªã©ã®ç ç©¶ããŒã ïŒ Executive Function and Diabetes: A Clinical Neuropsychology Perspective ïŒå®è¡æ©èœãšç³å°¿ç
ïŒèšåºç¥çµå¿çåŠç芳ç¹ããïŒ
ã¢ã¡ãªã«ç³å°¿ç åŠäŒïŒADAïŒã®åŠè¡èªãDiabetes Spectrumãæ²èŒïŒGlucose Extremes and Cognitive Function (Davis & Ferdous)